Enliven Therapeutics ELVN Accrued Expenses And Other Current Liabilities
Accrued Expenses And Other Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Enliven Therapeutics in its filing.
Tagged under the XBRL concept elvn:AccruedExpensesAndOtherCurrentLiabilities.
The official record: Enliven Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Enliven Therapeutics's accrued expenses and other current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Enliven Therapeutics's accrued expenses and other current liabilities?
- Enliven Therapeutics (ELVN) reported accrued expenses and other current liabilities of $9.85M in Q1 2026.
- How has Enliven Therapeutics's accrued expenses and other current liabilities changed year-over-year?
- Enliven Therapeutics's accrued expenses and other current liabilities decreased by 20.7% year-over-year, from $12.41M to $9.85M.
- What is the long-term trend for Enliven Therapeutics's accrued expenses and other current liabilities?
- Over 3 years (2022 to 2025), Enliven Therapeutics's accrued expenses and other current liabilities has grown at a 31.9% compound annual growth rate (CAGR), from $6.28M to $14.41M.
- What does accrued expenses and other current liabilities mean?
- This represents obligations for goods or services received that have been incurred but not yet invoiced or paid by the reporting date. It encompasses a variety of operational liabilities, such as accrued compensation, professional fees, and research-related costs common in clinical-stage biotechnology firms. Tracking this balance helps investors assess the company's short-term liquidity requirements and the timing of its operational cash outflows.